Common Side Effects (Both Medications): Gastrointestinal Side Effects (Most Common): These typically occur when starting treatment or increasing doses, and often improve over time: Nausea: Most frequent side effect for both medications Semaglutide: 44% of participants in clinical trials Tirzepatide: 30-37% depending on dose Usually mild to moderate Most common in weeks 1-8, improves with continued use Diarrhea: Semaglutide: 30% of participants Tirzepatide: 19-23% depending on dose Often resolves within a few weeks Staying hydrated helps manage symptoms Constipation: Semaglutide: 24% of participants Tirzepatide: 10-17% depending on dose Can alternate with diarrhea Fiber and hydration help Vomiting: Semaglutide: 24% of participants Tirzepatide: 9-17% depending on dose More common at higher doses May require dose reduction Abdominal Pain: Semaglutide: 20% of participants Tirzepatide: 8-11% depending on dose Usually mild, related to slower stomach emptying Other Common Side Effects: Appetite Changes: Decreased appetite (desired effect) Food aversions or taste changes Reduced interest in previously enjoyed foods Early satiety (feeling full quickly) Fatigue: Semaglutide: 11% of participants Tirzepatide: Similar rates Often related to reduced calorie intake May improve as body adjusts Injection Site Reactions: Mild redness, swelling, or itching at injection site Usually resolves within a few days Rotating injection sites helps minimize Headache: Occurs in 10-14% of participants with both medications Usually mild and temporary Often related to dehydration Side Effect Comparison: Why Tirzepatide May Have Fewer GI Side Effects: Despite being more potent, tirzepatide appears to cause slightly less nausea and GI distress
Monday, 02 February 2026 05:20 AM Umbrella Labs Cagrilintide Peptide Research Use Only Program Expands Laboratory Access For High Rigor Amylin Receptor, Calcitonin Receptor, And Neuroendocrine Signaling Bench Science Monday, 02 February 2026 05:20 AM Company Update TUCSON, AZ / ACCESS Newswire / February 2, 2026 / Umbrella Labs today announced an expanded research procurement program for cagrilintide peptide to support laboratories running amylin receptor complex profiling, calcitonin receptor signaling studies, and neuroendocrine pathway mapping in controlled bench environments
Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition
Following the UK and Switzerland, France Extends Public Insurance Coverage to Wegovy and Mounjaro, Marking a Paradigm Shift From Personal Responsibility to Treatable Disease Authored On Modified Major countries including France and the UK incorporate GLP-1 therapies into public healthcare systems Obesity redefined as a chronic disease under state-managed healthcare frameworks Drug reimbursement expected to reduce patient costs and expand treatment access France has decided to formally incorporate GLP-1 (glucagon-like peptide-1) obesity treatments into its public healthcare system
Each one of these changes can influence what the body releases in the urine
.png)
